Newsletters

[UCLA Health] Dr. Cristina Puig-Saus, an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine at UCLA and her research team have received grant from the National Cancer Institute to develop drug-based strategies that could enhance cancer immunotherapy for patients with melanoma and potentially other types of cancer.

[Science Advances] Researchers profiled longitudinal biopsies from patients with melanoma treated in the Phase Ib NIBIT-M4 epi-immunotherapy trial using single-cell multiome and spatial transcriptomics. Responders displayed enrichment of antigen presentation/interferon program and coordinated T and B cell expansion, whereas nonresponders retained stable neural crest–like clusters.

[Nature Medicine] Scientists presented the complete results of a Phase I trial investigating the safety and efficacy of autologous B7-H3-targeting chimeric antigen receptor T cell therapy for the treatment of recurrent glioblastoma.

[Cancer Research] Investigators identified innate immune remodeling as a key contributor to targeted therapy durability and identify NK cell recruitment, promoted in part by regression-associated macrophages, as a therapeutically actionable node for extending durability of response across oncogene-driven cancers.

[Science Advances] Scientists showed that in the first week of life, intestinal γδ T cells up-regulated many T cell activation and type 3 genes, while the postweaning period was dominated by induction of genes related to effector function, type 1 immunity, and cytotoxicity.

[Signal Transduction and Targeted Therapy] The authors integrate recent findings from oncology and inflammatory diseases to explore the origins, phenotypes, and trafficking mechanisms of migratory immune cells, highlighting how advances in understanding immune migration across cancer and inflammation can inform therapeutic innovation and precision immunomodulation.

[Experimental & Molecular Medicine] Scientists proposed a framework that overlays the cancer-immunity cycle with major metabolic checkpoints, including glucose and amino acid competition, acidosis and lipid overload, to clarify how distinct metabolic stresses create immune bottlenecks at different stages of the anti-tumour response.

[Proceedings of the National Academy of Sciences of the United States of America] By studying experimentally validated human antitumor, mutation-reactive CD4+ T cell receptors identified in tumors from patients with advanced solid cancers, researchers demonstrate that tumor mutation-reactive CD4+ T cells can be substantially enriched using cell surface protein markers ADGRG1 and CD86.

[Nature Communications] Investigators reported a spatially resolved single-cell atlas of human splenic NK cells and innate lymphoid cells (ILCs). This spatially resolved atlas provides a comprehensive reference of human splenic ILC organization, specialization, and interaction networks.

[Scientific Reports] Researchers studied immune cell and cytokine mobilization in lymphoma and breast cancer patients in response to 10-min and 30-min exercise. A 30-min acute exercise increased the numbers of circulating total leukocytes and lymphocytes, CD4+/- T cells, T helper 17 cells, Tregs, CD8+/- T cells, and CD56+ NK cells in lymphoma patients.

[Signal Transduction and Targeted Therapy] The authors highlight how CAR-based strategies can be adapted across diverse disease settings by redirecting engineered immune responses toward disease-sustaining cellular compartments.

[Cancer Research] Through head-to-head in vivo comparisons of potentially synergistic armor combinations, researchers demonstrated that T cells expressing a CAR plus IL12 and the decoy-resistant form of IL18 show strong efficacy against antigen-heterogeneous glioma in immunocompetent mice.